Table 1.
Clinical and molecular characteristics of patients in different treatment groups.
| Characteristics | Chemotherapy-only group | Allo-HSCT group | |||||
|---|---|---|---|---|---|---|---|
| High miR-20b (n = 45) | Low miR-20b (n = 45) | P | High miR-20b (n = 37) | Low miR-20b (n = 37) | P | ||
| Age/years, median (range) | 68 (33-88) | 62 (22-82) | 0.006* | 53 (18-65) | 49 (21-72) | 0.387* | |
| Age group/n (%) | 0.013§ | 0.601§ | |||||
| <60 years | 9 (20.0) | 20 (44.4) | 26 (70.3) | 28 (75.7) | |||
| ≥60 years | 36 (80.0) | 25 (55.6) | 11 (29.7) | 9 (24.3) | |||
| Gender/n (%) | 0.396§ | 0.348§ | |||||
| Male | 27 (60.0) | 23 (51.1) | 23 (62.2) | 19 (51.4) | |||
| Female | 18 (40.0) | 22 (48.9) | 14 (37.8) | 18 (48.6) | |||
| WBC/×109/L, median (range) | 9.9 (0.7-297.4) | 34 (1.4-298.4) | 0.090* | 12 (0.6-88.1) | 34 (1.2-223.8) | 0.001* | |
| BM blast/%, median (range) | 71 (30-99) | 72 (32-98) | 0.569* | 69 (30-95) | 71 (34-100) | 0.475* | |
| PB blast/%, median (range) | 16 (0-98) | 51 (0-97) | 0.043* | 35 (0-90) | 58.5 (8-96) | 0.003* | |
| FAB classification/n (%) | |||||||
| M0 | 7 (15.6) | 1 (2.2) | 0.058§ | 7 (18.9) | 2 (5.4) | 0.152§ | |
| M1 | 9 (20.0) | 11 (24.4) | 0.612§ | 10 (27.0) | 13 (35.1) | 0.451§ | |
| M2 | 9 (20.0) | 12 (26.7) | 0.455§ | 8 (21.6) | 11 (29.7) | 0.425§ | |
| M3 | 0 (0.0) | 0 (0.0) | 1.000§ | 2 (5.4) | 0 (0.0) | 0.493§ | |
| M4 | 11 (24.4) | 13 (28.9) | 0.634§ | 5 (13.5) | 9 (24.3) | 0.235§ | |
| M5 | 7 (15.6) | 6 (13.3) | 0.764§ | 3 (8.1) | 1 (2.7) | 0.615§ | |
| M6 | 0 (0.0) | 2 (4.4) | 0.494§ | 1 (2.7) | 0 (0.0) | 1.000§ | |
| M7 | 2 (4.4) | 0 (0.0) | 0.494§ | 1 (2.7) | 1 (2.7) | 1.000§ | |
| Cytogenetics (WHO)/n (%) | |||||||
| Normal | 22 (48.9) | 22 (48.9) | 1.000§ | 16 (43.2) | 18 (48.6) | 0.641§ | |
| Complex karyotype | 10 (22.2) | 2 (4.4) | 0.013§ | 11 (29.7) | 1 (2.7) | 0.002§ | |
| 8 Trisomy | 0 (0.0) | 0 (0.0) | 1.000§ | 1 (2.7) | 5 (13.5) | 0.199§ | |
| inv(16)/CBFβ-MYH11 | 0 (0.0) | 7 (15.6) | 0.012§ | 0 (0.0) | 5 (13.5) | 0.054§ | |
| 11q23/MLL | 2 (4.4) | 1 (2.2) | 1.000§ | 2 (5.4) | 1 (2.7) | 1.000§ | |
| -7/7q- | 3 (6.7) | 0 (0.0) | 0.242§ | 2 (5.4) | 1 (2.7) | 1.000§ | |
| t(15;17)/PML-RARA | 0 (0.0) | 0 (0.0) | 1.000§ | 2 (5.4) | 0 (0.0) | 0.494§ | |
| t(9;22)/BCR-ABL1 | 0 (0.0) | 1 (2.2) | 1.000§ | 1 (2.7) | 1 (2.7) | 1.000§ | |
| t(8;21)/RUNX1-RUNX1T1 | 0 (0.0) | 6 (13.3) | 0.026§ | 0 (0.0) | 1 (2.7) | 1.000§ | |
| Others | 8 (17.8) | 6 (13.3) | 0.561§ | 2 (5.4) | 4 (10.8) | 0.674§ | |
| Risk/n (%) | |||||||
| Good | 0 (0.0) | 13 (28.9) | 0.000§ | 2 (5.4) | 6 (16.7) | 0.152§ | |
| Intermediate | 26 (60.5) | 24 (53.3) | 0.500§ | 18 (48.6) | 23 (63.9) | 0.190§ | |
| Poor | 17 (39.5) | 8 (17.8) | 0.024§ | 17 (45.9) | 7 (19.4) | 0.016§ | |
| Chemotherapy regimen/n (%) | 0.009§ | 1.000§ | |||||
| 7+3 | 22 (48.9) | 34 (75.6) | 35 (94.6) | 36 (97.3) | |||
| Others | 23 (51.1) | 11 (24.4) | 2 (5.4) | 1 (2.7) | |||
| FLT3-ITD/n (%) | 1.000§ | 0.167§ | |||||
| Presence | 8 (17.8) | 8 (17.8) | 6 (16.2) | 11 (29.7) | |||
| Absence | 37 (82.2) | 37 (82.2) | 31 (83.8) | 26 (70.3) | |||
| NPM1/n (%) | 0.114§ | 0.295§ | |||||
| Mutation | 11 (24.4) | 18 (40.0) | 8 (21.6) | 12 (32.4) | |||
| Wild type | 34 (75.6) | 27 (60.0) | 29 (78.4) | 25 (67.6) | |||
| CEBPA/n (%) | 1.000§ | 0.005§ | |||||
| Single mutation | 1 (2.2) | 2 (4.4) | 0 (0.0) | 5 (13.5) | |||
| Double mutation | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (8.1) | |||
| Wild type | 44 (97.8) | 43 (95.6) | 37 (100) | 29 (78.4) | |||
| DNMT3A/n (%) | 0.814§ | 0.588§ | |||||
| Mutation | 13 (28.9) | 12 (26.7) | 10 (27.0) | 8 (21.6) | |||
| Wild type | 32 (71.1) | 33 (73.3) | 27 (73.0) | 29 (78.4) | |||
| IDH1/IDH2/n (%) | 0.581§ | 1.000§ | |||||
| Mutation | 7 (15.6) | 9 (20.0) | 9 (24.3) | 9 (24.3) | |||
| Wild type | 38 (84.4) | 36 (80.0) | 28 (75.7) | 28 (75.7) | |||
| RUNX1/n (%) | 0.714§ | 0.261§ | |||||
| Mutation | 5 (11.1) | 3 (6.7) | 6 (16.2) | 2 (5.4) | |||
| Wild type | 40 (88.9) | 42 (93.3) | 31 (83.8) | 35 (94.6) | |||
| MLL-PTD/n (%) | 1.000§ | 0.615§ | |||||
| Presence | 2 (4.4) | 3 (6.7) | 3 (8.1) | 1 (2.7) | |||
| Absence | 43 (95.6) | 42 (93.3) | 34 (91.9) | 36 (97.3) | |||
| NRAS/KRAS/n (%) | 0.764§ | 1.000§ | |||||
| Mutation | 6 (13.3) | 7 (15.6) | 4 (10.8) | 3 (8.1) | |||
| Wild type | 39 (86.7) | 38 (84.4) | 33 (89.2) | 34 (91.9) | |||
| TET2/n (%) | 0.215§ | 0.615§ | |||||
| Mutation | 8 (17.8) | 4 (8.9) | 1 (2.7) | 3 (8.1) | |||
| Wild type | 37 (82.2) | 41 (91.1) | 36 (97.3) | 34 (91.9) | |||
| TP53/n (%) | 0.004§ | 0.115§ | |||||
| Mutation | 10 (22.2) | 1 (2.2) | 4 (10.8) | 0 (0.0) | |||
| Wild type | 35 (77.8) | 44 (97.8) | 33 (89.2) | 37 (100) | |||
| Relapse/n (%) | 1.000§ | 0.619§ | |||||
| Yes | 16 (35.6) | 16 (35.6) | 24 (64.9) | 26 (70.3) | |||
| No | 29 (64.4) | 29 (64.4) | 13 (35.1) | 11 (29.7) | |||
WBC, white blood cell; BM, bone marrow; PB, peripheral blood; FAB, French American British; 7 + 3, “7” refers to Cytarabine given daily for 7 days, “3” refers to Idarubicin given daily for 3 days.
‘*’denotes Mann-Whitney U test; ‘§’ denotes chi-square test.